TAK-625

Phase 3Small molecule

Takeda

TAK-625 is one of 8 small molecule programs targeting Intrahepatic Cholestasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholestasisActive, not recruiting

Intrahepatic CholestasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Intrahepatic Cholestasis

#DrugCompanyPhaseTrials

Actigall

Glucophage

1 3

Livmarli

MMirum Pharmaceuticals, Inc.

Phase 3

5 4

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Phase 3

2 5

Remaxol

PPOLYSAN Scientific & Technological Pharmaceutical Company

Phase 3

1 6

TAK-625

Takeda

Phase 3

1 7

Volixibat

MMirum Pharmaceuticals, Inc.

Phase 2

1 8

Bylvay

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alagille Syndrome1 trial

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Completed· Takeda logo

Takeda·Phase 3·NCT05543174·7 enrolled

Intrahepatic Cholestasis1 trial

A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Completed· Takeda logo

Takeda·Phase 3·NCT05543187·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TAK-625. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-625 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-625. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

TAK-625

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alagille Syndrome1 trial

Intrahepatic Cholestasis1 trial

References

Drug Info

Quick Facts

Related News